普莱柯生物工程股份有限公司 证券代码：603566 证券简称：普莱柯 公告编号：2023-020 关于召开 2022 年度暨 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 普莱柯生物工程股份有限公司（以下简称"公司"）已于 2023 年 4 月 25 日发 布公司2022年年度报告及2023年第一季度报告的公告，为便于广大投资者更全 面深入地了解公司2022年度和2023年第一季度经营成果、财务状况，公司计划 于 2023 年 5 月 8 日上午 10:00-11:30 举行 2022 年度暨 2023 年第一季度业绩说 明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以视频结合网络互动式召开，公司将针对 2022 年度和 2023 年第一季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟 通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开时间、地点 （一）会议召开时间：2023 年 5 月 8 日上午 10:00-11 ...

证券代码：603566 证券简称：普莱柯 普莱柯生物工程股份有限公司投资者关系活动记录表 编号：2022-002 | --- | --- | --- | |----------------|------------------------------|----------------------------------| | | | | | | □ 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 | □ 业绩说明会 | | 投资者关系活动 | □ 新闻发布会 | □ 路演活动 | | 类别 | □ 现场参观 | √电话会议 | | | □ 其他 | （请用文字说明其他活动内容） | | | 中信证券：彭家乐、盛夏、王聪 | | | | 中金公司：张宇茜、单妍 | | | | 贝莱德：贺维艺 | | | | 比邻投资：赖坤洪 | | | | 博时基金；梅思哲 | | | | 博裕资本：王淑铖 | | | | 渤海保险：路博麟 | | | | 财通基金：沈犁 | | | | 大家资产：胡筱 | | | | 东吴基金：蔡秋实、刘浩宇 | | | | 富国基金：朱征星 | | | 参与单位名称及 | 高毅 ...

2022 年第三季度报告 单位：元 币种：人民币 证券代码：603566 证券简称：普莱柯 普莱柯生物工程股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中 财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 主要会计数据和财务指标 | --- | --- | --- | --- | --- | |------------------------------------------------|----------------|----------------------------------------|----------------|------------------------------------- ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2022, with a year-on-year growth of XX%[21] - The company's operating revenue decreased by 11.48% year-on-year, primarily due to a downturn in the pig and poultry breeding industry, leading to a decline in sales of vaccines and pharmaceuticals[25] - Net profit attributable to shareholders dropped by 50.94% year-on-year, with a non-recurring net profit decrease of 50.68%, attributed to reduced revenue and increased sales and management expenses[25] - The company achieved a revenue of CNY 513 million in the first half of 2022, a decrease of 11.48% year-on-year[51] - Net profit attributable to shareholders was CNY 80.26 million, down 50.94% compared to the same period last year[51] - Basic earnings per share fell by 50.00% to CNY 0.26, while diluted earnings per share also decreased by 50.00% to CNY 0.26[24] - The company's operating income for the first half of 2022 was CNY 265,353,067.91, a decrease of approximately 11.4% compared to CNY 299,484,090.79 in the same period of 2021[168] - The net profit for the first half of 2022 was CNY 80,259,074.97, down 51.0% from CNY 163,601,790.64 in the first half of 2021[166] - The company's total profit for the first half of 2022 was CNY 91,638,091.27, a decline of 52.0% from CNY 191,376,522.12 in the previous year[166] Cash Flow and Investments - The net cash flow from operating activities increased by 249.08% year-on-year, mainly due to improved cash management practices[25] - The net cash flow from operating activities increased significantly to CNY 82,089,525.97, up from CNY 23,516,298.69 in the same period last year, representing a growth of 248.5%[175] - Cash inflow from investment activities totaled CNY 125,976,957.54, down 77.5% from CNY 560,261,003.12 in the previous year[178] - Cash outflow for investment activities was CNY 133,537,825.52, a decrease of 75% compared to CNY 532,823,703.52 in the first half of 2021[178] - The net increase in cash and cash equivalents for the first half of 2022 was CNY 46,078,349.22, compared to a decrease of CNY -106,468,450.35 in the first half of 2021[178] Research and Development - Research and development efforts are being intensified, with an increase in R&D investment by XX% compared to the previous year[21] - R&D investment totaled CNY 23.56 million, accounting for 4.59% of revenue[52] - The company has established national-level R&D platforms to enhance its innovation capabilities and address major animal disease challenges[37] - Research and development expenses for the first half of 2022 were CNY 12,766,356.31, significantly reduced from CNY 25,360,516.46 in the first half of 2021, indicating a 49.7% decrease[168] Market Expansion and Product Development - New product development includes the launch of the pig circovirus type 2 and mycoplasma pneumonia inactivated vaccine, which is expected to enhance market competitiveness[21] - The company is expanding its market presence, targeting new regions and increasing distribution channels to boost sales[21] - The company has initiated strategic acquisitions to enhance its product portfolio and market share, focusing on complementary businesses[21] - The company is developing a subunit vaccine for African swine fever in collaboration with the Chinese Academy of Agricultural Sciences, aiming for emergency evaluation submission[52] - The company has launched a new veterinary drug registration for its live vaccine against pseudorabies, expected to be the first approved for the prevalent strain[53] Financial Position and Assets - The company has maintained a strong financial position, with total assets reaching RMB XX billion, an increase of XX% from the previous year[21] - The total assets increased by 5.89% year-on-year, reaching CNY 2,295,915,831.60[24] - The company's total assets amounted to ¥2,295,915,831.60, up from ¥2,168,280,813.81, which is an increase of approximately 5.9%[151] - The company's cash and cash equivalents increased to ¥219,416,158.75 from ¥168,832,480.34, representing a growth of approximately 30.0%[148] Environmental Compliance - The company was listed as a key pollutant discharge unit by the Henan Provincial Ecological Environment Department[89] - The company has a complete and well-functioning wastewater treatment facility, ensuring compliance with discharge standards[93] - All construction projects during the reporting period adhered to environmental impact assessment requirements[94] - The company conducted regular monitoring of pollutants, confirming compliance with national environmental regulations[96] Shareholder and Governance Commitments - The company’s major shareholders have committed to avoiding any business activities that compete with the company[102] - The company’s board and senior management are committed to fulfilling all public commitments made during the initial public offering[102] - The company committed to repurchase all newly issued shares if any false statements or omissions are identified in the prospectus, with the repurchase price not lower than the issuance price plus interest based on the one-year bank deposit rate[105] - The company will stop cash dividend plans and the payment of salaries to directors and senior management if it fails to fulfill public commitments[105] - The company has established a long-term commitment to transparency and accountability in its financial disclosures and operations[106]

2022 年第一季度报告 单位：元 币种：人民币 1 / 11 证券代码：603566 证券简称：普莱柯 普莱柯生物工程股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|----------|-------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期增减 变动幅度 (%) | | 营业收入 | | 245,291,876.69 ...

Financial Performance - The company achieved an annual revenue of CNY 1,098,568,103.53 in 2021, representing an 18.31% increase compared to the previous year[26]. - Net profit attributable to shareholders was CNY 244,137,406.56, reflecting a 7.20% growth year-over-year[26]. - The net profit after deducting non-recurring gains and losses reached CNY 184,868,648.42, marking a 21.05% increase from the prior year[26]. - The company's cash flow from operating activities was CNY 212,533,722.96, down 18.83% compared to 2020[26]. - The total assets of the company at the end of 2021 were CNY 2,168,280,813.81, a 6.87% increase from the end of 2020[26]. - The net assets attributable to shareholders reached CNY 1,800,452,116.65, reflecting a 5.31% increase year-over-year[26]. - The company achieved operating revenue of CNY 1,098,568,103.53, representing an 18.31% increase compared to the previous year[77]. - The sales revenue from swine vaccines increased by 47.23% year-on-year, while poultry vaccines and antibody sales grew by 7.04%[79]. - The gross margin for veterinary pharmaceuticals was 65.29%, an increase of 0.80 percentage points compared to the previous year[80]. - The company reported a total revenue of CNY 1.07 billion, with a gross margin of 65.29%, reflecting an 18.47% increase in revenue year-on-year[108]. Research and Development - Research and development expenses totaled CNY 85,572,300, accounting for 7.79% of total revenue[39]. - The company applied for 18 domestic and international invention patents during the year, with 38 patents granted[39]. - The company is advancing the development of genetically engineered subunit vaccines for major animal diseases, including African swine fever and foot-and-mouth disease, with clinical trial applications expected within the year[40]. - The company has established two major innovation platforms, including the Henan Provincial Veterinary Drug Technology Innovation Center, showcasing its leadership in technological innovation[41]. - The company has formed strategic partnerships with various research institutions to enhance its R&D capabilities[70]. - The company is focusing on innovative product development, particularly in the areas of next-generation genetic engineering vaccines and multi-valent vaccines, with a series of projects targeting strategic and market-demand products[109]. - Key research projects include the African Swine Fever subunit vaccine and the recombinant foot-and-mouth disease subunit vaccine, both currently in the preclinical research stage[112]. - The company has a robust pipeline of veterinary vaccines and pharmaceuticals, with ongoing projects aimed at addressing significant health challenges in livestock and pets[112]. Market and Product Development - The company has established a wholly-owned subsidiary focused on pet pharmaceuticals, with multiple products in development and clinical trial stages[49]. - The company is actively exploring marketing strategies that combine professional channel promotion and online marketing for its pet products[50]. - The company has made significant progress in the development of pet vaccines and chemical drugs, with several products receiving clinical trial approvals[49]. - The company aims to expand its market presence through innovative product offerings and strategic research initiatives[109]. - The company is committed to advancing its research capabilities to meet industry needs and enhance its competitive position[109]. - The company is focusing on expanding its market presence in the veterinary pharmaceutical industry, which is characterized by high concentration among large enterprises[103]. - The company has launched several new products, including a series of soluble powders and oral solutions, with specific registration numbers and expected release dates in 2026[121][122]. - The company is focusing on expanding its product line with new formulations such as injectable solutions and disinfectants, enhancing its market presence[126]. Corporate Governance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[5]. - The company’s financial report has been confirmed for its authenticity and completeness by its management team[4]. - The company maintains strict independence from its controlling shareholder, with no interference in decision-making or operations[164]. - The company has established a complete independent accounting system and financial management procedures[164]. - The company held 3 shareholder meetings during the reporting period, ensuring equal rights for all shareholders, especially minority shareholders[163]. - The board of directors consists of 9 members, including 3 independent directors, and held 11 meetings during the reporting period[163]. - The supervisory board convened 5 times during the reporting period, adhering to legal and regulatory requirements[164]. - The company has a clear three-year shareholder return plan for 2021-2023, which was also approved in the recent meetings[167]. Risk Management - The company has outlined various risks it may face in its production and operation processes, detailed in the report[8]. - The company faces risks from animal epidemics, regulatory changes, intensified market competition, product development challenges, and quality assurance issues[156][157][158][161]. Employee and Management Structure - The company has a total of 1,809 employees, with 976 in the parent company and 833 in major subsidiaries[198]. - The employee composition includes 838 production personnel, 509 sales personnel, 276 technical personnel, 41 financial personnel, and 145 administrative personnel[198]. - The company has optimized its salary structure in 2021, establishing a management salary system based on job sequences and improving the salary structure to enhance job security and highlight value contribution[199]. - The company has maintained a stable management structure with no changes in key positions during the reporting period[171]. Future Outlook - The company plans to raise up to 900 million RMB through a private placement to fund the construction of a high-pathogenic avian influenza inactivated vaccine production base and other projects, enhancing its industrial layout and production capacity[51]. - The company aims to complete the relocation and expansion of its production base by the end of 2023, which will help overcome current capacity bottlenecks and capitalize on market opportunities as high-pathogenic avian influenza vaccines exit government procurement by 2025[54]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of $100 million allocated for potential deals[181]. - The company has set ambitious performance guidance for the upcoming fiscal year, aiming for a substantial increase in revenue and market share[123].

2021 年第三季度报告 单位：元 币种：人民币 证券代码：603566 证券简称：普莱柯 普莱柯生物工程股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期比 年初至报告期 | --- | --- | --- | --- | --- | |-----------------------------------------------|----------|---------------------------|-------------------------------------|--------------- ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2021, achieving a total of 500 million RMB, representing a growth of 25% compared to the same period last year[18]. - The company's operating revenue for the first half of 2021 was ¥579,230,884.47, representing a 37.34% increase compared to ¥421,758,167.79 in the same period last year[26]. - The net profit attributable to shareholders was ¥163,601,790.64, up 36.30% from ¥120,026,748.15 year-on-year[26]. - The net profit after deducting non-recurring gains and losses increased by 44.25%, reaching ¥147,465,861.99 compared to ¥102,230,868.70 in the previous year[26]. - The company achieved a revenue of CNY 579 million in the first half of 2021, representing a growth of 37.34% compared to the same period last year[50]. - The net profit attributable to the parent company was CNY 164 million, an increase of 36.30% year-on-year, while the net profit after deducting non-recurring gains and losses was CNY 147 million, up 44.25% year-on-year[50]. - The total comprehensive income for the period reached ¥163,601,790.64, up from ¥120,026,748.15 in the previous period, representing a growth of approximately 36.2%[139]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2021, representing a 15% year-over-year growth[100]. Research and Development - The management highlighted the importance of technological advancements, with a 30% increase in R&D spending, totaling 150 million RMB for the current fiscal year[18]. - The company's R&D investment totaled CNY 39.57 million, accounting for 6.83% of revenue, supporting various R&D activities[51]. - The company is actively developing a bivalent three-component genetic engineering subunit vaccine for highly pathogenic avian influenza (H5+H7) and has submitted clinical trial applications for it[51]. - The company is collaborating with research institutes to advance the clinical research of a composite subunit vaccine for African swine fever[54]. - The company focuses on innovation, with gene-engineered vaccines and multi-valent vaccines gaining popularity among users[33]. - The company has established national-level R&D platforms, employing over 260 technical staff to drive product development[44]. - The company has formed a rapid and efficient product R&D system based on market demand and competitive analysis[36]. Market Expansion and Strategy - The company is actively pursuing market expansion strategies, targeting new regions in Southeast Asia, with an estimated investment of 50 million RMB for market entry[18]. - The company has initiated a strategic acquisition of a local competitor, expected to close by Q4 2021, which will enhance market capabilities[106]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by 2023[104]. - The company plans to implement a new marketing strategy aimed at increasing brand awareness, with a budget allocation of 50 million RMB[100]. Operational Challenges and Risks - The company has identified potential risks in the supply chain, which could impact production capacity by up to 10% if not addressed promptly[18]. - The company faces significant operational risks due to potential outbreaks of animal diseases, which could drastically reduce the number of animals and impact business performance[69]. - Regulatory risks are increasing as government policies regarding veterinary drug development, production, and sales become more stringent, potentially delaying R&D progress and increasing costs[70]. - R&D risks are present due to the lengthy and complex process of developing and registering new veterinary drugs, which may lead to delays or failures[72]. Sustainability and Environmental Responsibility - The company remains committed to sustainability initiatives, allocating 20 million RMB towards environmental and social responsibility projects in 2021[18]. - The company was recognized as a key pollutant discharge unit by the Henan Provincial Ecological Environment Department, indicating its environmental responsibilities[81]. - The company achieved a wastewater treatment standard with COD emissions of 11.9038 tons/year and ammonia nitrogen emissions of 1.1687 tons/year[83]. - The company has implemented an emergency response plan for environmental incidents, which is regularly trained and rehearsed[88]. - The company has ensured that all construction projects comply with environmental impact assessment regulations[87]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,688[111]. - The largest shareholder, Zhang Xuke, held 107,619,672 shares, representing 33.47% of the total shares[111]. - The second-largest shareholder, Sun Jinzhu, held 29,915,348 shares, accounting for 9.31%[114]. - The top ten shareholders collectively held a significant portion of the company's shares, with the largest holding being 33.47%[111]. - The company did not report any changes in its share capital structure during the reporting period[111]. Financial Position and Assets - The company's total assets at the end of the reporting period were ¥2,060,963,273.62, a 1.59% increase from ¥2,028,803,645.60 at the end of the previous year[26]. - The company's cash and cash equivalents stood at RMB 147,277,834.81, down from RMB 253,653,282.38, representing a decrease of approximately 42%[124]. - Accounts receivable increased to RMB 319,151,031.08 from RMB 205,117,342.36, marking a significant rise of about 55.5%[124]. - The total liabilities reached RMB 345,037,050.73, compared to RMB 319,158,363.35 at the end of 2020, reflecting an increase of about 8.1%[126]. - The company's equity attributable to shareholders was RMB 1,715,926,222.89, slightly up from RMB 1,709,645,282.25, indicating a growth of approximately 0.4%[126].

证券代码：603566 证券简称：普莱柯 公告编号：2021-027 普莱柯生物工程股份有限公司 关于参加河南辖区上市公司 2021 年投资者网上集体接待日 活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强与投资者的互动交流，使广大投资者能更深入全面地了解普莱 柯生物工程股份有限公司（以下简称"公司"）情况，本公司将参加由河南证监 局与河南省上市公司协会、深圳市全景网络有限公司举办的 2021 年河南辖区上 市公司投资者网上集体接待日活动。现将有关事项公告如下： 公司定于 2021 年 6 月 8 日（周二）16：00-17：20 参加在全景网举办的"真 诚沟通 传递价值"河南辖区上市公司 2021 年投资者网上集体接待日活动，本次 活动将采用网络远程的方式举行，投资者可登录"全景•路演天下" （http://rs.p5w.net）参与本次互动交流。 出席本次网上集体接待日活动的人员为董事会秘书赵锐先生。 欢迎广大投资者积极参与。 特此公告 普莱柯生物工程股份有限公司 董 事 会 2021 年 6 ...

Financial Performance - Operating revenue for the period was CNY 308,684,677.37, representing a year-on-year growth of 59.81%[12] - Net profit attributable to shareholders was CNY 86,849,170.37, up 46.21% from the same period last year[12] - Basic earnings per share rose by 55.56% to CNY 0.28[12] - The company's operating revenue for Q1 2021 was CNY 159,481,775.01, an increase from CNY 105,745,260.14 in Q1 2020, representing a growth of approximately 50.8%[50] - The net profit attributable to shareholders for Q1 2021 was CNY 86,849,170.37, compared to CNY 59,400,827.59 in Q1 2020, reflecting an increase of about 46.2%[49] - The total profit for Q1 2021 was CNY 101,678,458.31, compared to CNY 67,040,371.34 in Q1 2020, representing an increase of approximately 51.6%[49] - The total comprehensive income for Q1 2021 was CNY 86,849,170.37, compared to CNY 59,400,827.59 in Q1 2020, indicating an increase of about 46.2%[50] Revenue Breakdown - Revenue from pig vaccines surged by 191.13% to CNY 110,235,441.30 compared to the previous year[15] - Revenue from chemical drugs increased by 63.22% to CNY 100,298,781.19 year-on-year[15] - Operating revenue rose by 59.81% to ¥308,684,677.37 compared to ¥193,156,705.35, primarily driven by sales of veterinary biological products and chemical drugs[21] Cash Flow - The net cash flow from operating activities was negative at CNY -14,564,672.22, a decline of 640.38% compared to the previous year[12] - Operating cash inflow totaled CNY 233,335,334.97, an increase from CNY 164,741,820.69 year-over-year[58] - Operating cash outflow amounted to CNY 247,900,007.19, compared to CNY 162,046,556.19 in the previous year[58] - Cash flow from investing activities showed a net outflow of CNY -52,913,502.84, contrasting with a net inflow of CNY 176,152,112.24 in the previous year[60] - Cash flow from financing activities resulted in a net outflow of CNY -100,004,090.87, consistent with the previous year's outflow[60] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 2,117,453,881.78, an increase of 4.37% compared to the end of the previous year[12] - Non-current assets totaled ¥1,167,747,772.84, up from ¥1,149,343,204.16, indicating a growth in long-term investments[30] - Total liabilities amounted to ¥320,959,429.16, slightly increasing from ¥319,158,363.35, reflecting stable financial leverage[33] - The company's total liabilities decreased to ¥207,189,424.84 from ¥213,673,007.42, a reduction of approximately 3%[41] Shareholder Information - The company reported a total of 12,807 shareholders at the end of the reporting period[15] - The top shareholder, Zhang Xuke, holds 33.47% of the shares, totaling 107,619,672 shares[15] Expenses - Operating costs increased by 42.00% to ¥97,889,843.70 from ¥68,937,426.28, reflecting higher sales volumes[21] - Sales expenses surged by 102.17% to ¥66,530,190.77 from ¥32,907,838.56, attributed to increased marketing expenses[21] - Research and development expenses in Q1 2021 amounted to ¥19,883,507.77, compared to ¥16,846,927.91 in Q1 2020, indicating a 17.9% increase[44] - Research and development expenses for Q1 2021 were CNY 12,468,104.83, slightly up from CNY 11,595,555.03 in Q1 2020, showing a year-over-year increase of about 7.5%[50] Other Income and Losses - Other income decreased by 80.17% to ¥990,002.15 from ¥4,991,297.68, primarily due to reduced government subsidies related to daily operations[21] - Investment income fell by 57.43% to ¥875,665.33 from ¥2,057,077.35, mainly due to decreased returns from associated companies[21] - The company incurred a credit impairment loss of CNY 1,909,521.53 in Q1 2021, compared to CNY 2,095,828.79 in Q1 2020, reflecting a decrease of approximately 8.8%[49] - The company's other income for Q1 2021 was CNY 990,002.15, significantly lower than CNY 4,991,297.68 in Q1 2020, indicating a decline of about 80.2%[49] Inventory and Accounts - Accounts receivable increased by 42.57% to ¥292,426,520.56 from ¥205,117,342.36 due to increased revenue[21] - Inventory and contract assets rose to ¥91,418,376.91 from ¥71,772,524.63, marking a 27.4% increase[41] - The company reported a decrease in accounts payable from ¥22,167,632.28 in Q1 2020 to ¥20,581,035.94 in Q1 2021, a decline of 7.2%[41]